F1CDx approved in Japan as a CDx of ROS1+NSCLC for Rozlytrek

Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200102_IR_Chugai_Approval_ROS1_CDx_en.pdf Do not hesitate to contact us for any further questions. With best regards,
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news